9 Meters Biopharma (the “Company”) is focused on developing therapies for gastrointestinal (GI) disorders that are rare, orphan, and have high unmet need. 9 Meters is publicly traded (NASDAQ: NMTR) and was formed through the merger of Innovate Biopharmaceuticals and RDD Pharma completed on April 30, 2020, as well as the acquisition of Naia Rare Diseases completed on May 7, 2020. The company’s co-lead assets are NM-002 (exenatide), a long-acting injectable GLP-1 analogue for short bowel syndrome, and Larazotide for celiac disease. 9 Meters started a Phase 1b/2a trial for NM-002 in early July of 2020 with data expected in 1H21, and data from its ongoing Phase 3 study for Larazotide is expected in 2H21. The company is also developing two earlier stage assets – NM-003, a long-acting GLP-2 injectable entering Phase 1, and NM-004, an oral, gut-restricted immunomodulator that is Phase 2a ready.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):